Ardelyx (ARDX) vs Syndax Pharmaceuticals (SNDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Ardelyx (ARDX) has outperformed Syndax Pharmaceuticals (SNDX) over the past year, losing 44.8% versus a loss of 50.0%. Over five years, ARDX leads with a +234.8% price change compared with -47.1% for SNDX. Syndax Pharmaceuticals is the larger company by market cap ($785.0 million vs $751.6 million), about 1.0 times the size.
Ardelyx converts more of its revenue into profit, with a net margin of -15.1% versus -165.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARDX | SNDX |
|---|---|---|
| Share price | $2.99 | $8.72 |
| Market cap | $751.60M | $785.05M |
| 1-day change | -2.29% | -4.49% |
| YTD return | -48.71% | -58.50% |
| 1-year return | -44.83% | -50.00% |
| 5-year return | +234.83% | -47.09% |
| Forward P/E | 18.92 | — |
| EPS (TTM) | $-0.23 | $-2.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $407.32M | $172.35M |
| Revenue growth (YoY) | +22.09% | +627.84% |
| Net income (latest FY) | $-61.60M | $-285.42M |
| Gross margin | 90.29% | — |
| Operating margin | -10.06% | -158.45% |
| Net margin | -15.12% | -165.60% |
| 52-week high | $8.40 | $25.59 |
| 52-week low | $2.80 | $8.41 |
| Distance from 52-week high | -64.40% | -65.92% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +318.06% | +306.54% |
| Average volume | 4.46M | 2.63M |
| Shares outstanding | 251.37M | 90.03M |
| Employees | 489 | 298 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Ardelyx is more profitable, keeping -15.1 cents of every revenue dollar as net income versus -165.6 cents for Syndax Pharmaceuticals.
- Syndax Pharmaceuticals grew revenue faster in its latest fiscal year (+627.84% vs +22.09%).
About Ardelyx
ARDX stock →Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 489 employees
About Syndax Pharmaceuticals
SNDX stock →Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 298 employees
ARDX vs SNDX FAQ
Which is bigger, Ardelyx or Syndax Pharmaceuticals?
Syndax Pharmaceuticals (SNDX) is larger, with a market capitalization of $785.05M compared with $751.60M for Ardelyx (ARDX).
Which stock has performed better over the past year, ARDX or SNDX?
ARDX returned -44.83% over the past 12 months, compared with -50.00% for SNDX (price return, excluding dividends). Past performance does not predict future results.
Are Ardelyx and Syndax Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.